In This Article:
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL 2025 meeting and deliver a scientific presentation in the late-breaking oral presentation session. The meeting will be held May 7-10, 2025, in Amsterdam, Netherlands.
“We are excited that data from our NAVIGATE study, evaluating belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension, has been accepted as a late-breaking oral presentation. The selection of our abstract for an oral late-breaking session underscores the significance of these findings within the hepatology community. Through our belapectin program, we continue to advance understanding of liver cirrhosis — a condition that has long been overlooked despite its profound impact on patients’ lives. We’re looking forward to sharing the data with the scientific community at the EASL Congress. Additionally, we continue to analyze biomarker data from NAVIGATE, including the stand-alone 18-month trial data, as well as the 57 subjects completing 36-months. As patients are no longer being treated, we expect to share additional results in the second quarter of 2025.” said Dr. Khurram Jamil, Chief Medical Officer at Galectin Therapeutics.
Poster Presentation Details
Title: Belapectin at 2 mg/kg/LBW Reduces Varices Development in MASH Cirrhosis with Portal Hypertension: Results from the NAVIGATE Trial
Abstract Number: LB-006/ LB25183
Session: Poster, Complication of Cirrhosis, Portal Hypertension
Authors: Naim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, Mitchell Shiffman, Eric J. Lawitz, Edward Mena, Nadege Gunn, Khurram Jamil, Stephen A. Harrison, Naga Chalasani
Date, time & location: Saturday, May 10, 2024: 1:00 PM - 2:30 PM, CET RAI Amsterdam
The presentation will be available for viewing by EASL attendees and will be posted on our website under the “Events & Presentations” page shortly after the congress.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.